Clinical Trials Directory
This study has two parts. In the first part, called Phase 1a, doctors will test different amounts of a medicine called PHN-012 to find the safest dose. In the second part, called Phase 1b, doctors will see how well PHN-012 works against cancer. The medicine will be given through an IV, which means it goes into a vein. You will get the medicine every 21 days until your cancer gets worse or you have to stop because of bad side effects.
We are doing this study to find out if an experimental drug called PHTS001 (the study drug) is a safe and effective option for people who have advanced relapsed or refractory solid tumors.
We are doing this study to find out if the combination of two hormonal drugs, giredestrant and fulvestrant, are a safe and effective option if they are given with the study doctor's choice of a class of medicines called CDK4/6 inhibitors to people who have ER-positive, HER2-negative breast cancer that is resistant to standard treatments.
In this study, people will take a special medicine called PLX-61639 one time each day. Before starting, there will be a time called the screening period that can last up to 28 days. During this time, doctors will check to see if you can join the study. After that, you will take the medicine in 28-day cycles. You will go to the clinic often for check-ups. These visits will include blood tests, heart tests, and scans. Some visits might take the whole day. You will also write in a diary to keep track of when you take the medicine. The amount of medicine you get may be different depending on when you join the study. You can stay in the study as long as the doctor thinks the medicine is helping you.
We are doing this study to find out if the combination of an experimental drug called ONC201 (the study drug) with paxalisib is an effective option for patients with a diffuse midline glioma (DMG). We also want to see how much of these drugs are absorbed by tumor tissue in patients with brain tumors.
This study is for people with type 1 diabetes (T1D). Their immune system attacks cells in the body that make insulin. A new treatment called GNTI-122 is made from their own blood cells and may help stop this attack. People will be in one of three groups: low dose, high dose, or high dose with another medicine called rapamycin. The study includes several visits to check if the treatment works and is safe.
We are doing this study to find out if an experimental drug called ADI-PEG 20 (the study drug) combined with two types of FDA-approved chemotherapies (gemcitabine and docetaxel) is a safe and effective option for people who have leiomyosarcoma.